WO2015142061A1 - 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 - Google Patents
줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 Download PDFInfo
- Publication number
- WO2015142061A1 WO2015142061A1 PCT/KR2015/002640 KR2015002640W WO2015142061A1 WO 2015142061 A1 WO2015142061 A1 WO 2015142061A1 KR 2015002640 W KR2015002640 W KR 2015002640W WO 2015142061 A1 WO2015142061 A1 WO 2015142061A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- brain
- treatment
- pharmaceutical composition
- cells
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a composition for treating brain inflammatory diseases comprising stem cell-derived exosomes as an active ingredient.
- Stem cells are undifferentiated cells and have the ability to differentiate into two or more different types of cells with self-replicating ability. Stem cells can be classified into totipotent stem cells, pluripotent stem cells, and multipotent stem cells according to their differentiation capacity. It can be classified into stem cells and adult stem cells. Embryonic stem cells are derived from preimplantation fertilized eggs or developing fetal genital tissues, while adult stem cells are derived from organs present in the adult, such as bone marrow, brain, liver, and pancreas.
- Pluripotent stem cells are pluripotent cells that can develop into a complete individual. Cells up to 8 cell stages after fertilization of eggs and sperm have these properties. Transplantation into the uterus can result in one complete individual.
- Pluripotent stem cells are cells that can develop into various cells and tissues derived from ectoderm, mesoderm, and endodermal layer.Inner cell masses located inside the blastocyst appearing after 4-5 days of fertilization. ), which are called embryonic stem cells and differentiate into various tissue cells, but do not form new organisms.
- Multipotent stem cells are stem cells that can only differentiate into cells specific to the tissues and organs that contain them, as well as the growth and development of individual tissues and organs in the prenatal, neonatal, and adult phases. It is involved in maintaining homeostasis of adult tissues and inducing regeneration in case of tissue damage.
- Adult tissue-specific pluripotent cells are collectively called adult stem cells.
- Adult stem cells are cells that are already present in various organs of the human body, and developed into stem cells, and are characterized by differentiation only into specific tissues. Recently, however, it is noted that experiments using adult stem cells to differentiate into various tissues such as hepatocytes have been successful.
- Stem cells are characterized by self-renewing, differentiation, and immortality.
- Adult stem cells from a variety of tissues are generally more limited than embryonic stem cells. It is widely used for research because ethical problems can be avoided.
- stem cells have been attempted by applying stem cells to various diseases such as cerebral infarction, traumatic nerve injury, and musculoskeletal disorders.
- the current technical level is only a simple extraction and culture / proliferation of stem cells and the injection of them.
- clinical research has shown that such stem cell treatments have not shown a clear effect.
- researches using various genetically engineered stem cells have been conducted, but cell therapy using genetic engineering has limitations that are difficult to apply in the human body due to ethical issues.
- exosomes are small vesicles of membrane structure secreted from various kinds of cells.
- the diameter of the exosomes is reported to be approximately 30-100 nm.
- Exosomes have been observed in electron microscopy to originate in specific compartments within cells called multivesicular bodies (MVBs) and to be released and secreted out of the cell, rather than falling directly off the plasma membrane. That is, when fusion occurs between the polycystic body and the plasma membrane, the vesicles are released into the extracellular environment, which is called exosomes.
- MVBs multivesicular bodies
- exosomes are made of, but not only red blood cells, but also various immune cells and tumor cells, including B-lymphocytes, T-lymphocytes, dendritic cells, platelets, macrophages, etc.
- Stem cells are also known to produce and secrete exosomes in living conditions.
- exosomes derived from stem cells contain nuclear components as well as receptors and proteins are known to play an intercellular communication role.
- the exosomes derived from the stem cells contain a relatively small amount of animal serum compared to the stem cells may also exclude the risk of symptoms (zoonosis) due to animal serum infection.
- zoonosis due to animal serum infection.
- the brain inflammatory disease refers to an inflammatory disease occurring in the brain by a specific cause, and includes a concept including all encephalitis, meningitis, meningoencephalitis, and the like.
- Encephalitis is a general term for inflammatory diseases of the brain parenchyma and is distinguished from inflammation (meningitis) that occurs in the meninges surrounding the brain. When meningitis and encephalitis are called meningoencephalitis.
- Encephalitis can be broadly classified into infectious, vasculitis, neoplastic, chemical and idiopathic depending on the cause, and can be reclassified as encephalitis for specific etiologies according to specific details.
- the present inventors continued to develop new therapeutic agents for brain inflammatory diseases.
- stem cell-derived exosomes suppress the death of cells caused by inflammation in neurons and have excellent therapeutic effects in animal models of brain inflammatory diseases.
- the present invention was completed.
- An object of the present invention to provide a pharmaceutical composition for the treatment of brain inflammatory diseases comprising stem cell-derived exosomes as an active ingredient.
- the present invention provides a pharmaceutical composition for the treatment of brain inflammatory diseases comprising stem cell-derived exosomes as an active ingredient.
- Stem cell-derived exosomes inhibits cell death due to inflammation in neurons, increases survival in animal models of brain inflammatory diseases, and significantly increases brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema. It has an excellent therapeutic effect such as reducing, and can be usefully used for the treatment of brain inflammatory diseases.
- FIG. 1 is a diagram confirming the process of exosomes secreted from the stem cells by thrombin through TEM image analysis (left: before thrombin treatment, right: after thrombin treatment).
- FIG. 2 is a diagram confirming whether the exosome markers CD63 and CD9 are normally expressed in the stem cell-derived exosomes isolated in the present invention.
- 3 is a diagram showing the viability of neurons according to the concentration of LPS when treated with LPS neurons.
- Figure 4 is a diagram showing the survival of neurons when treated with LPS to the neurons, when treated with the stem cell-derived exosome of the present invention.
- 5 is a diagram showing the survival rate during the experiment using the brain inflammatory disease animal model.
- Figure 6 is a diagram showing the results of measuring the brain weight after the end of the experiment using the animal model of brain inflammatory disease.
- Figure 7 is a diagram showing the change in the brain MRI scan results and brain damage site / entire brain area 1 day and 6 days after the induction of inflammatory diseases of the brain.
- Figure 8 is a diagram showing the expression level of inflammatory cytokines in brain tissue according to the administration of stem cell-derived exosomes in animal models of brain inflammatory diseases.
- Figure 9 is a diagram showing the expression of protein in brain tissue according to the administration of stem cell-derived exosomes in animal models of brain inflammatory disease.
- the present invention provides a pharmaceutical composition for the treatment of brain inflammatory diseases comprising stem cell-derived exosomes as an active ingredient.
- Stem cells in the present invention refers to cells that have the ability to differentiate into two or more different types of cells while having self-replicating ability as undifferentiated cells.
- Stem cells of the present invention may be autologous or allogeneic stem cells, may be from any type of animal, including humans and non-human mammals, and is not limited to whether the stem cells are derived from adults or embryos Do not.
- Stem cells of the present invention include embryonic stem cells or adult stem cells, preferably adult stem cells.
- the adult stem cells may be mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells, multipotent stem cells or amniotic epithelial cells, preferably mesenchymal stem cells
- the mesenchymal stem cells may be mesenchymal stem cells derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amnion, and placenta, but is not limited thereto.
- Exosomes in the present invention refers to the small vesicles of the membrane structure secreted from various cells.
- the diameter of the exosome is approximately 30-100 nm, which means that the vesicle is released into the extracellular environment due to the fusion of the polycystic body and the plasma membrane.
- Brain inflammatory disease in the present invention is a general term for all inflammatory diseases occurring in the brain, including encephalitis, meningitis, meningoencephalitis, preferably meningitis, more preferably bacterial infective meningitis.
- the meningitis can be divided into viral and non-viral depending on the cause.
- the viral meningitis includes, but is not limited to, meningitis caused by herpes simplex virus, arbovirus, varicella zoster virus, Epstein bar virus, cytomegalovirus, Japanese encephalitis virus, and the like.
- the non-viral meningitis includes bacteria (for example, Haemophilus influenzae, Neisseria encephalitis, Streptococcus, Streptococcus, Staphylococcus, Escherichia coli, Streptococcus, etc.), parasites (for example cyanobacteria, toxoplasma), fungi Meningitis caused by bacteria, protozoa (eg, amoeba, etc.), and the like.
- bacteria for example, Haemophilus influenzae, Neisseria encephalitis, Streptococcus, Streptococcus, Staphylococcus, Escherichia coli, Streptococcus, etc.
- parasites for example cyanobacteria, toxoplasma
- fungi Meningitis caused by bacteria protozoa (eg, amoeba, etc.), and the like.
- stem cell-derived exosomes inhibit cell death by inflammation in neurons, increase survival in animal models of brain inflammatory diseases, and brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema. It was confirmed that there is an excellent treatment effect for brain inflammatory diseases such as significantly reduced.
- the stem cell-derived exosomes according to the present invention can be usefully used as a medicine for the treatment of brain inflammatory diseases.
- composition of the present invention may further contain one or more known active ingredients having a therapeutic effect of brain inflammatory diseases together with stem cell-derived exosomes.
- composition of the present invention may further contain an exosome internal material together with the stem cell-derived exosomes.
- the exosome inner material includes, but is not limited to, proteins, lipids, mRNA, microRNA, etc. derived from tissues or cells derived from the exosomes.
- composition of the present invention may further comprise a suitable carrier commonly used in the manufacture of pharmaceutical compositions.
- a suitable carrier commonly used in the manufacture of pharmaceutical compositions.
- a preservative, a painless agent, a solubilizer, or a stabilizer may be further included, and in the case of a topical administration, a base, an excipient, a lubricant, or a preservative may be further included.
- compositions of the present invention can be administered in a dosage form, formulated in a unit dosage form suitable for administration in the body of a subject according to conventional methods in the pharmaceutical art.
- Formulations suitable for this purpose include parenteral injectables such as injectable ampoules, injectables such as infusion bags, sprays such as aerosol preparations and the like.
- the injection ampoule may be mixed with the injection solution immediately before use, and physiological saline, glucose, Ringer's solution, etc. may be used as the injection solution.
- the infusion bag may be made of polyvinyl chloride or polyethylene.
- Administration in the present invention means providing the subject with the compositions of the present invention in any suitable manner.
- the pharmaceutical composition of the present invention can be administered to a subject by various routes. All modes of administration can be expected, for example, can be administered by oral, rectal, intravascular (vein, arterial, etc.), intramuscular, subcutaneous, intrauterine or cerebrovascular injections, preferably Implantation or transplantation directly into the ventricles of individuals in need of treatment is not limited thereto.
- Preferred dosages of the pharmaceutical compositions of the present invention depend on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration and can be appropriately selected by those skilled in the art. Administration of the composition may be administered once a day, may be divided several times, but is not limited thereto.
- compositions of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the treatment of brain inflammatory diseases.
- the fetus was taken out of the white paper at 18.5 days of gestational age, and the cerebral cortex was separated, and then cultured with primary glial cells and neurons for 7 days. After treatment with LPS (lipopolysaccharides) by concentration, the cell death was observed. The results are shown in FIG.
- Example 2 After treating 15 ⁇ g of the stem cell-derived exosomes obtained in Example 1 to neurons treated with LPS at a concentration of 10 ⁇ g / ml as described above, a cell count kit (Dojindo, Kumamoto, Japan) was used. Cell viability was measured. The results are shown in FIG.
- E. coli Esscherichia
- CFU colony forming unit
- the mesenchymal stem cell-derived exosomes obtained in Example 1 at 11 days of age (P11), which is 1 day after modeling (induced bacterial infective meningitis) (20 ⁇ g) was diluted in 10 ul PBS and then slowly administered into the right ventricle of the experimental group (MEN + MSC exosome) white paper using a stereotecnic frame under nitric oxide (NO) inhalation anesthesia.
- MEN + MSC exosome a stereotecnic frame under nitric oxide (NO) inhalation anesthesia.
- physiological saline was administered in the right ventricle of the white paper
- MEN + fibroblast fibroblast-derived exosomes were administered in the right ventricle of the white paper.
- the brain weight of the meningitis control group significantly reduced compared to the normal group (NC)
- the brain of the experimental group MEN + MSC exosome
- mesenchymal stem cell-derived exosomes It was confirmed that the weight was not significantly different from the normal group.
- the meningitis control group (MEN, Saline) showed severe brain parenchymal edema and ventricular dilatation, and brain damage was observed, but the experimental group administered with mesenchymal stem cell-derived exosomes (MEN). + MSC exosomes were found to significantly improve the extent of brain damage during the experimental period compared to the meningitis control group (MEN) and control group (MEN + fibroblast).
- Example 3-2 After separating the protein from the brain tissue isolated in Example 3-2, inflammatory cytokines (IL-1 ⁇ , IL-1 ⁇ , IL-6, TNF-) through a conventionally known enzyme-linked immunosorbent assay (ELISA) method ⁇ ) expression level was measured, and the expression levels of Caspase-3 and GFAP were analyzed by Western blot.
- IL-1 ⁇ , IL-1 ⁇ , IL-6, TNF- IL-1 ⁇ , IL-1 ⁇ , IL-6, TNF-
- ELISA enzyme-linked immunosorbent assay
- the level of inflammatory cytokines in the brain was rapidly increased in the meningitis control group (MEN) compared to the normal group (NC).
- the experimental group administered with mesenchymal stem cell-derived exosomes showed significantly improved levels of inflammatory cytokines in the brain compared to the meningitis control group, which was compared with the control group (MEN + fibroblast). It was a remarkably good result.
- stem cell-derived exosomes inhibit the death of cells by inflammation in neurons, increase survival rate in animal models of brain inflammatory diseases, and brain damage and inflammatory cytokine levels due to inflammatory reactions such as edema. It has been confirmed that it has an excellent treatment effect for brain inflammatory diseases such as significantly reduced.
Abstract
Description
Claims (9)
- 줄기세포 유래 엑소좀(exosome)을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 1항에 있어서, 상기 줄기세포는 배아 줄기세포 또는 성체 줄기세포인 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 2항에 있어서, 상기 성체 줄기세포는 중간엽 줄기세포, 인간 조직 유래 중간엽 기질세포(mesenchymal stromal cell), 인간 조직 유래 중간엽 줄기세포, 다분화능 줄기세포 및 양막상피세포로 구성된 군에서 선택되는 줄기세포인 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 3항에 있어서, 상기 중간엽 줄기세포는 제대, 제대혈, 골수, 지방, 근육, 신경, 피부, 양막 및 태반으로 구성된 군에서 선택된 1종 이상의 조직 유래인 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 1항에 있어서, 상기 뇌 염증성 질환은 뇌염, 뇌수막염 및 수막뇌염으로 이루어진 군으로부터 선택된 1종 이상인 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 5항에 있어서, 상기 뇌수막염은 세균, 기생충, 곰팡이균, 원충류 및 바이러스로 이루어진 군으로부터 선택된 1종 이상에 의해 유발된 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 6항에 있어서, 상기 뇌수막염은 세균 감염성 뇌수막염인 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 1항 내지 제 7항 중 어느 한 항에 있어서, 상기 조성물은 엑소좀 외에 엑소좀 내부 물질을 더 포함하는 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
- 제 1항 내지 제 7항 중 어느 한 항에 있어서, 상기 조성물은 경구, 직장 내, 혈관 내, 근육 내, 피하, 자궁 내, 뇌혈관 내 또는 뇌실 내로 투여되는 것을 특징으로 하는, 뇌 염증성 질환의 치료용 약학적 조성물.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15764229.9A EP3120857B1 (en) | 2014-03-18 | 2015-03-18 | Compositions for use in treating inflammatory brain disease comprising stem-cell-derived exosomes as an active ingredient |
JP2016557971A JP6295341B2 (ja) | 2014-03-18 | 2015-03-18 | 幹細胞由来エキソソームを有効成分として含む脳炎症性疾患の治療用組成物 |
US15/126,053 US9919011B2 (en) | 2014-03-18 | 2015-03-18 | Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0031624 | 2014-03-18 | ||
KR20140031624 | 2014-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015142061A1 true WO2015142061A1 (ko) | 2015-09-24 |
Family
ID=54144950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/002640 WO2015142061A1 (ko) | 2014-03-18 | 2015-03-18 | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9919011B2 (ko) |
EP (1) | EP3120857B1 (ko) |
JP (1) | JP6295341B2 (ko) |
KR (1) | KR101661847B1 (ko) |
WO (1) | WO2015142061A1 (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018085587A1 (en) * | 2016-11-02 | 2018-05-11 | Prockop Darwin J | Exosomes and uses thereof in diseases of the brain |
JP2019511509A (ja) * | 2016-04-15 | 2019-04-25 | サムソン ライフ パブリック ウェルフェア ファウンデーション | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 |
EP3479831A4 (en) * | 2016-07-01 | 2020-03-25 | Samsung Life Public Welfare Foundation | COMPOSITION COMPRISING AN EXOSOME DERIVED FROM THROMBIN TREATED STEM CELLS FOR THE TREATMENT OF A WOUND OF THE SKIN |
CN117384857A (zh) * | 2023-12-08 | 2024-01-12 | 上海兴瑞一达生物科技有限公司 | 一种pf4基因修饰的间充质干细胞外泌体及其应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3189828B1 (en) * | 2014-11-07 | 2020-07-29 | Exostemtech Co., Ltd. | Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement |
WO2017087500A1 (en) | 2015-11-18 | 2017-05-26 | University Of Georgia Research Foundation, Inc. | Neural cell extracellular vessicles |
KR101973284B1 (ko) * | 2017-01-16 | 2019-04-29 | 사회복지법인 삼성생명공익재단 | 신생아 hie 치료용 조성물 |
WO2019165279A1 (en) * | 2018-02-23 | 2019-08-29 | EMULATE, Inc. | Organs-on-chips as a platform for epigenetics discovery |
KR102646145B1 (ko) | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
JP7079984B2 (ja) | 2018-07-28 | 2022-06-03 | エクソコバイオ インコーポレイテッド | エキソソームの凍結乾燥方法 |
KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
WO2020027467A1 (ko) * | 2018-07-30 | 2020-02-06 | 주식회사 엑소코바이오 | 줄기세포 유래 엑소좀의 동결건조제제 및 이를 유효성분으로 포함하는 항염조성물 |
CA3114901C (en) * | 2018-10-04 | 2023-12-19 | Synaptec Network, Inc. | Systems and methods for delivering exosomes through the blood-brain barrier |
US11725190B2 (en) | 2019-02-22 | 2023-08-15 | EMULATE, Inc. | Microfluidic proximal tubule kidney-on-chip |
JP2023550328A (ja) * | 2020-11-26 | 2023-12-01 | サムスン ライフ パブリック ウェルフェア ファウンデーション | トロンビン処理幹細胞に由来したエクソソームを含む感染性疾患治療用組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100081003A (ko) * | 2009-01-05 | 2010-07-14 | 서울대학교산학협력단 | 인간 신경 줄기세포 유래 면역조절 활성을 갖는 미세소낭 및 이를 유효성분으로 하는 면역조절제 |
US20130195899A1 (en) * | 2012-01-31 | 2013-08-01 | Medistem, Inc. | Therapeutic immune modulation by stem cell secreted exosomes |
WO2014013029A1 (en) * | 2012-07-18 | 2014-01-23 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (mscs) in the prevention and therapy of inflammatory conditions |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2788780B1 (fr) | 1999-01-27 | 2001-03-30 | Ap Cells Inc | Procede de preparation de vesicules membranaires |
KR20050088118A (ko) | 2002-12-13 | 2005-09-01 | 세로고스 | 배양 배지 조성물, 배양 방법, 및 얻어진 근원세포, 및그들의 용도 |
NZ548926A (en) | 2004-02-09 | 2009-07-31 | Regenion Gmbh | Inhibitors of TGF-R signaling for treatment of CNS disorders |
CA2565115A1 (en) | 2004-05-03 | 2005-11-10 | Peter Maccallum Cancer Institute | Methods for stem cell expansion and differentiation |
CN109432126B (zh) | 2011-03-11 | 2022-06-14 | 儿童医学中心公司 | 与间充质干细胞外来体相关的方法和组合物 |
JPWO2013039000A1 (ja) | 2011-09-13 | 2015-03-26 | 孝広 落谷 | アルツハイマー病の予防または治療のための医薬品 |
HUE056817T2 (hu) | 2011-12-30 | 2022-03-28 | Amit Patel | Eljárások és készítmények allogén sejt klinikai származtatására és terápiás alkalmazások |
SG11201406336YA (en) | 2012-04-03 | 2014-11-27 | Reneuron Ltd | Stem cell microparticles |
WO2014013258A1 (en) * | 2012-07-19 | 2014-01-23 | Reneuron Limited | Stem cell microparticles |
KR101405620B1 (ko) * | 2012-09-07 | 2014-06-10 | 사회복지법인 삼성생명공익재단 | 중간엽 줄기세포를 포함하는 미숙아 뇌실 내 출혈 치료용 조성물 |
US9982233B2 (en) * | 2013-12-12 | 2018-05-29 | Samsung Life Public Welfare Foundation | Method for promoting generation of stem cell-derived exosome by using thrombin |
US20170121685A1 (en) * | 2015-11-02 | 2017-05-04 | Tigenix S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
-
2015
- 2015-03-18 KR KR1020150037679A patent/KR101661847B1/ko active IP Right Grant
- 2015-03-18 JP JP2016557971A patent/JP6295341B2/ja active Active
- 2015-03-18 WO PCT/KR2015/002640 patent/WO2015142061A1/ko active Application Filing
- 2015-03-18 EP EP15764229.9A patent/EP3120857B1/en active Active
- 2015-03-18 US US15/126,053 patent/US9919011B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100081003A (ko) * | 2009-01-05 | 2010-07-14 | 서울대학교산학협력단 | 인간 신경 줄기세포 유래 면역조절 활성을 갖는 미세소낭 및 이를 유효성분으로 하는 면역조절제 |
US20130195899A1 (en) * | 2012-01-31 | 2013-08-01 | Medistem, Inc. | Therapeutic immune modulation by stem cell secreted exosomes |
WO2014013029A1 (en) * | 2012-07-18 | 2014-01-23 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (mscs) in the prevention and therapy of inflammatory conditions |
Non-Patent Citations (2)
Title |
---|
KIM, S. H. ET AL.: "Effective Treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL -4", THE JOURNAL OF IMMUNOLOGY, vol. 179, no. 4, 2007, pages 2242 - 2249, XP055358624 * |
XIN, H. ET AL.: "Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 33, 2013, pages 1711 - 1715, XP055226654 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019511509A (ja) * | 2016-04-15 | 2019-04-25 | サムソン ライフ パブリック ウェルフェア ファウンデーション | トロンビン処理幹細胞に由来するエキソソームを含む慢性肺疾患治療用組成物 |
EP3479831A4 (en) * | 2016-07-01 | 2020-03-25 | Samsung Life Public Welfare Foundation | COMPOSITION COMPRISING AN EXOSOME DERIVED FROM THROMBIN TREATED STEM CELLS FOR THE TREATMENT OF A WOUND OF THE SKIN |
WO2018085587A1 (en) * | 2016-11-02 | 2018-05-11 | Prockop Darwin J | Exosomes and uses thereof in diseases of the brain |
CN117384857A (zh) * | 2023-12-08 | 2024-01-12 | 上海兴瑞一达生物科技有限公司 | 一种pf4基因修饰的间充质干细胞外泌体及其应用 |
CN117384857B (zh) * | 2023-12-08 | 2024-03-19 | 上海兴瑞一达生物科技有限公司 | 一种pf4基因修饰的间充质干细胞外泌体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20150108795A (ko) | 2015-09-30 |
EP3120857A4 (en) | 2017-12-13 |
JP2017521357A (ja) | 2017-08-03 |
US9919011B2 (en) | 2018-03-20 |
EP3120857B1 (en) | 2021-02-17 |
KR101661847B1 (ko) | 2016-09-30 |
JP6295341B2 (ja) | 2018-03-14 |
EP3120857A1 (en) | 2017-01-25 |
US20170087187A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015142061A1 (ko) | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 | |
WO2015088286A1 (ko) | 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물 | |
Mahla | Stem cells applications in regenerative medicine and disease therapeutics | |
KR100837167B1 (ko) | 제대혈로부터 분리 또는 증식된 세포를 포함하는 발달성,만성 폐질환 치료용 조성물 | |
Guo et al. | Three-dimensional spheroid-cultured mesenchymal stem cells devoid of embolism attenuate brain stroke injury after intra-arterial injection | |
WO2017179840A1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 만성폐질환 치료용 조성물 | |
CN110461344B (zh) | 用于治疗新生儿hie的组合物 | |
US10668111B2 (en) | Use of umbilical mesenchymal stem cells for treating pulmonary fibrosis | |
WO2021210872A1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 당뇨병성 피부질환 예방 또는 치료용 조성물 | |
KR102464099B1 (ko) | 다능성 간세포에 의한 허혈재관류 폐장애의 경감 및 치료 | |
WO2014129792A1 (ko) | 줄기세포를 유효성분으로 포함하는 뇌 염증성 질환의 치료용 조성물 | |
KR101405620B1 (ko) | 중간엽 줄기세포를 포함하는 미숙아 뇌실 내 출혈 치료용 조성물 | |
Bērziņš et al. | Characterisation and Safety of Canine Adipose-Derived Stem Cells | |
WO2022114730A2 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 감염성 질환 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15764229 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15126053 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2016557971 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015764229 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015764229 Country of ref document: EP |